Paloma Partners’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,997
| Closed | -$643K | – | 306 |
|
|
2024
Q3 | $643K | Sell |
1,997
-7,679
| -79% | -$2.51M | 0.02% | 541 |
|
|
2024
Q2 | $3.02M | Buy |
+9,676
| New | +$2.84M | 0.09% | 254 |
|
|
2024
Q1 | – | Sell |
-4
| Closed | -$1.15K | – | 768 |
|
|
2023
Q4 | $1.15K | Buy |
+4
| New | +$1.09K | ﹤0.01% | 711 |
|
|
2023
Q3 | – | Sell |
-11,383
| Closed | -$2.53M | – | 716 |
|
|
2023
Q2 | $2.53M | Buy |
11,383
+9,983
| +713% | +$2.32M | 0.09% | 210 |
|
|
2023
Q1 | $338K | Sell |
1,400
-11,840
| -89% | -$2.91M | 0.01% | 553 |
|
|
2022
Q4 | $3.48M | Buy |
+13,240
| New | +$3.55M | 0.16% | 106 |
|
|
2022
Q3 | – | Sell |
-4,100
| Closed | -$998K | – | 999 |
|
|
2022
Q2 | $998K | Sell |
4,100
-2,065
| -33% | -$506K | 0.04% | 427 |
|
|
2022
Q1 | $1.49M | Sell |
6,165
-46,927
| -88% | -$10.8M | 0.04% | 315 |
|
|
2021
Q4 | $11.9M | Buy |
+53,092
| New | +$11.2M | 0.18% | 74 |
|
|
2021
Q2 | – | Sell |
-8,544
| Closed | -$2.13M | – | 1752 |
|
|
2021
Q1 | $2.13M | Buy |
8,544
+7,467
| +693% | +$1.78M | 0.04% | 397 |
|
|
2020
Q4 | $248K | Buy |
+1,077
| New | +$248K | 0.01% | 1264 |
|
|
2020
Q3 | – | Sell |
-827
| Closed | -$195K | – | 2050 |
|
|
2020
Q2 | $195K | Sell |
827
-6,926
| -89% | -$1.58M | ﹤0.01% | 1710 |
|
|
2020
Q1 | $1.57M | Buy |
7,753
+6,543
| +541% | +$1.43M | 0.09% | 190 |
|
|
2019
Q4 | $291K | Sell |
1,210
-137,586
| -99% | -$30.3M | ﹤0.01% | 1776 |
|
|
2019
Q3 | $26.9M | Buy |
138,796
+39,090
| +39% | +$7.5M | 0.56% | 23 |
|
|
2019
Q2 | $18.4M | Buy |
99,706
+34,608
| +53% | +$6.2M | 0.31% | 45 |
|
|
2019
Q1 | $12.4M | Sell |
65,098
-2,679
| -4% | -$512K | 0.3% | 51 |
|
|
2018
Q4 | $13.2M | Sell |
67,777
-106,744
| -61% | -$20.8M | 0.4% | 42 |
|
|
2018
Q3 | $36.2M | Buy |
174,521
+75,521
| +76% | +$14.9M | 0.66% | 22 |
|
|
2018
Q2 | $18.3M | Buy |
99,000
+59,214
| +149% | +$10.5M | 0.33% | 36 |
|
|
2018
Q1 | $6.78M | Buy |
39,786
+33,346
| +518% | +$6.12M | 0.11% | 130 |
|
|
2017
Q4 | $1.12M | Sell |
6,440
-17,395
| -73% | -$3.08M | 0.02% | 986 |
|
|
2017
Q3 | $4.44M | Sell |
23,835
-23,665
| -50% | -$4.19M | 0.06% | 323 |
|
|
2017
Q2 | $8.18M | Buy |
47,500
+8,971
| +23% | +$1.46M | 0.1% | 186 |
|
|
2017
Q1 | $6.32M | Sell |
38,529
-77,028
| -67% | -$12.8M | 0.08% | 236 |
|
|
2016
Q4 | $16.9M | Buy |
115,557
+61,534
| +114% | +$9.26M | 0.17% | 67 |
|
|
2016
Q3 | $9.01M | Sell |
54,023
-20,458
| -27% | -$3.46M | 0.11% | 110 |
|
|
2016
Q2 | $11.3M | Buy |
74,481
+63,514
| +579% | +$9.87M | 0.12% | 85 |
|
|
2016
Q1 | $1.65M | Sell |
10,967
-17,939
| -62% | -$2.67M | 0.03% | 577 |
|
|
2015
Q4 | $4.69M | Buy |
28,906
+22,973
| +387% | +$3.61M | 0.12% | 132 |
|
|
2015
Q3 | $821K | Sell |
5,933
-9,681
| -62% | -$1.53M | 0.02% | 758 |
|
|
2015
Q2 | $2.4M | Buy |
15,614
+5,129
| +49% | +$822K | 0.05% | 383 |
|
|
2015
Q1 | $1.68M | Sell |
10,485
-6,014
| -36% | -$947K | 0.05% | 338 |
|
|
2014
Q4 | $2.63M | Buy |
+16,499
| New | +$2.57M | 0.11% | 182 |
|
|
2014
Q3 | – | Sell |
-1,800
| Closed | -$213K | – | 996 |
|
|
2014
Q2 | $213K | Buy |
+1,800
| New | +$208K | 0.01% | 943 |
|
|
2013
Q3 | – | Sell |
-34,090
| Closed | -$3.36M | – | 906 |
|
|
2013
Q2 | $3.36M | Buy |
+34,090
| New | +$3.54M | 0.19% | 114 |
|
Other funds holding AMGN
Paloma Partners's AMGN Position: Q4 2024 in Review
Paloma Partners sold out of Amgen (AMGN) in Q4 2024, closing a stake of 1,997 shares — an estimated $643K sold.
Paloma Partners first reported a position in AMGN in Q2 2013 and held it in 36 quarters. The position peaked at $36.2M in Q3 2018. 2,855 funds tracked by Wall St. Rank hold AMGN as of Q4 2024.
- Paloma Partners reported no remaining Amgen position as of Q4 2024 after selling out during the quarter.
- Paloma Partners sold 1,997 Amgen shares in Q4 2024, an estimated $643K.
- Paloma Partners first reported a position in Amgen in Q2 2013 and held it in 36 quarters.
- Paloma Partners's Amgen position peaked at $36.2M in Q3 2018.
- 2,855 funds tracked by Wall St. Rank held Amgen as of Q4 2024.
Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.